Quick access


Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes





Start of patient enrolment on 21st of June 2016

2571 patients enrolled (2502 patients randomised)
181   sites open for recruitment

Status as of 11th of July 2022


Planned number of participants


36 randomised and treated patients pending to archieve recruitment target



17 european countries:

Belgium, Bulgaria, Germany, France, Greece, United Kingdom, Italy, The Netherlands, Austria, Poland, Portugal, Romania, Sweden, Spain, Czech Republic, Ukraine, Hungary



Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, deGroot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, and Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019; 0, 1–9.
doi: 10.1093/europace/euz172

Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P. Atrial high-rate episodes and stroke prevention. Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279. Epub 2016 Feb 29.

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.



Atrial Fibrillation NETwork (AFNET), Münster, Germany


Scientific leader

International Chief Investigator:

Prof. Paulus Kirchhof, Hamburg, Germany


Registration NCT02618577

 ISRCTN 17309850

EudraCT number: 2015-003997-33